Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 in pulmonary arterial hypertension
NCT05135000Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing LTP001 with Placebo (2 arms). Primary endpoint: Pulmonary Vascular Resistance at 25 weeks. Started Jun 2022; status: terminated.
02
Drugs
LTP001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05135000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135000.